# Strive, Inc.: financial statements, quarterly

ASST · Nasdaq · CIK 1920406 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/asst.md) · [Financials](/companies/asst/financials.md) · [Filings](/companies/asst/filings.md) · [Insiders](/companies/asst/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/asst/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001213900-24-043619.md) | [0.1](/filings/0001213900-24-069032.md) | [0.1](/filings/0001213900-24-098471.md) | [0.1 d](/filings/0001213900-25-026431.md) | [0.1](/filings/0001213900-25-044239.md) | [0.1](/filings/0001213900-25-071724.md) | [1.0](/filings/0001628280-25-052343.md) | [1.0 d](/filings/0001628280-26-019879.md) | [1.4](/filings/0001628280-26-034805.md) | [1.5](/filings/0001628280-26-054985.md) | [2.8](/filings/0001628280-26-034805.md) | [2.9](/filings/0001628280-26-054985.md) |
| Research and development | $m | [0.0](/filings/0001213900-24-043619.md) | [0.0 d](/filings/0001213900-24-069032.md) | [0.0 d](/filings/0001213900-24-098471.md) | [0.0 d](/filings/0001213900-25-026431.md) | [0.1](/filings/0001213900-25-044239.md) | [0.1 d](/filings/0001213900-25-071724.md) | [0.1 d](/filings/0001213900-24-098471.md) | [0.1 d](/filings/0001213900-25-026431.md) | [0.1](/filings/0001213900-25-044239.md) | [0.1 d](/filings/0001213900-25-071724.md) | not reported | not reported |
| Operating income | $m | [(1.1)](/filings/0001213900-24-043619.md) | [(1.3)](/filings/0001213900-24-069032.md) | [(1.2)](/filings/0001213900-24-098471.md) | [(1.3) d](/filings/0001213900-25-026431.md) | [(1.4)](/filings/0001213900-25-044239.md) | [(1.7)](/filings/0001213900-25-071724.md) | [(7.0)](/filings/0001628280-25-052343.md) | [(4.7) d](/filings/0001628280-26-019879.md) | [(4.1)](/filings/0001628280-26-034805.md) | [(3.7)](/filings/0001628280-26-054985.md) | [(313)](/filings/0001628280-26-034805.md) | [(258)](/filings/0001628280-26-054985.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-25-044239.md) | [0.0](/filings/0001213900-25-071724.md) | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-25-052343.md) | [0.0 d](/filings/0001628280-26-019879.md) | [0.0](/filings/0001628280-26-034805.md) | [0.0](/filings/0001628280-26-054985.md) | [0.0](/filings/0001628280-26-034805.md) | [0.0](/filings/0001628280-26-054985.md) |
| Net income | $m | [(1.1)](/filings/0001213900-24-098471.md) | [(1.3)](/filings/0001213900-24-098471.md) | [(1.2)](/filings/0001213900-24-098471.md) | [(1.3) d](/filings/0001213900-25-026431.md) | [(4.8)](/filings/0001628280-25-052343.md) | [(5.9)](/filings/0001628280-25-052343.md) | [(6.8)](/filings/0001628280-25-052343.md) | [(4.1)](/filings/0001628280-25-052343.md) | [(3.7)](/filings/0001628280-26-054985.md) | [(8.9)](/filings/0001628280-26-054985.md) | [(266)](/filings/0001628280-26-054985.md) | [(258)](/filings/0001628280-26-054985.md) |
| Diluted EPS | $ per share | [(0.06)](/filings/0001213900-24-043619.md) | [(0.48)](/filings/0001213900-24-069032.md) | [(0.43)](/filings/0001213900-24-098471.md) | not reported | [(0.49)](/filings/0001213900-25-044239.md) | [(0.58)](/filings/0001213900-25-071724.md) | [(3.06)](/filings/0001628280-25-052343.md) | not reported | [(1.65)](/filings/0001628280-26-034805.md) | [(3.86)](/filings/0001628280-26-054985.md) | [(4.53)](/filings/0001628280-26-034805.md) | [(3.77)](/filings/0001628280-26-054985.md) |
| Basic EPS | $ per share | [(0.09)](/filings/0001213900-24-043619.md) | [(0.48)](/filings/0001213900-24-069032.md) | [(0.43)](/filings/0001213900-24-098471.md) | not reported | [(0.49)](/filings/0001213900-25-044239.md) | [(0.58)](/filings/0001213900-25-071724.md) | [(3.06)](/filings/0001628280-25-052343.md) | not reported | [(1.65)](/filings/0001628280-26-034805.md) | [(3.86)](/filings/0001628280-26-054985.md) | [(4.53)](/filings/0001628280-26-034805.md) | [(3.77)](/filings/0001628280-26-054985.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | period not labelled (2025-09-11) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.9](/filings/0001213900-24-098471.md) | [1.9](/filings/0001213900-24-043619.md) | [1.9](/filings/0001213900-24-069032.md) | [2.1](/filings/0001213900-24-098471.md) | [6.2](/filings/0001628280-26-019879.md) | [4.2](/filings/0001213900-25-044239.md) | [2.5](/filings/0001213900-25-071724.md) | not reported | [109](/filings/0001628280-25-052343.md) | [67.5](/filings/0001628280-26-054985.md) | [95.1](/filings/0001628280-26-034805.md) | [145](/filings/0001628280-26-054985.md) |
| Current assets | $m | [3.0](/filings/0001213900-25-026431.md) | [2.0](/filings/0001213900-24-043619.md) | [2.1](/filings/0001213900-24-069032.md) | [2.2](/filings/0001213900-24-098471.md) | [23.8](/filings/0001628280-26-019879.md) | [4.5](/filings/0001213900-25-044239.md) | [2.7](/filings/0001213900-25-071724.md) | not reported | [114](/filings/0001628280-25-052343.md) | [71.8](/filings/0001628280-26-054985.md) | [151](/filings/0001628280-26-034805.md) | [193](/filings/0001628280-26-054985.md) |
| Total assets | $m | [3.1](/filings/0001213900-25-026431.md) | [2.1](/filings/0001213900-24-043619.md) | [2.4](/filings/0001213900-24-069032.md) | [2.6](/filings/0001213900-24-098471.md) | [28.2](/filings/0001628280-26-019879.md) | [5.0](/filings/0001213900-25-044239.md) | [3.3](/filings/0001213900-25-071724.md) | not reported | [793](/filings/0001628280-25-052343.md) | [746](/filings/0001628280-26-054985.md) | [1,100](/filings/0001628280-26-034805.md) | [1,377](/filings/0001628280-26-054985.md) |
| Current liabilities | $m | [0.2](/filings/0001213900-25-026431.md) | [0.3](/filings/0001213900-24-043619.md) | [0.3](/filings/0001213900-24-069032.md) | [0.3](/filings/0001213900-24-098471.md) | [3.3](/filings/0001628280-26-019879.md) | [0.5](/filings/0001213900-25-044239.md) | [0.6](/filings/0001213900-25-071724.md) | not reported | [9.5](/filings/0001628280-25-052343.md) | [10.8](/filings/0001628280-26-054985.md) | [13.2](/filings/0001628280-26-034805.md) | [25.3](/filings/0001628280-26-054985.md) |
| Total liabilities | $m | [0.2](/filings/0001213900-25-026431.md) | [0.3](/filings/0001213900-24-043619.md) | [0.3](/filings/0001213900-24-069032.md) | [0.3](/filings/0001213900-24-098471.md) | [4.9](/filings/0001628280-26-019879.md) | [0.5](/filings/0001213900-25-044239.md) | [0.6](/filings/0001213900-25-071724.md) | not reported | [13.1](/filings/0001628280-25-052343.md) | [14.3](/filings/0001628280-26-054985.md) | [26.3](/filings/0001628280-26-034805.md) | [28.6](/filings/0001628280-26-054985.md) |
| Shareholders' equity | $m | [16.1](/filings/0001628280-26-019879.md) | [11.3](/filings/0001628280-25-052343.md) | [5.4](/filings/0001628280-25-052343.md) | [27.5](/filings/0001628280-25-052343.md) | [23.3](/filings/0001628280-26-054985.md) | [19.6](/filings/0001628280-26-054985.md) | [10.7](/filings/0001628280-26-054985.md) | [(4.1)](/filings/0001628280-26-019879.md) | [779](/filings/0001628280-25-052343.md) | [582](/filings/0001628280-26-054985.md) | [715](/filings/0001628280-26-054985.md) | [646](/filings/0001628280-26-054985.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.8)](/filings/0001213900-24-043619.md) | [(1.1) d](/filings/0001213900-24-069032.md) | [(1.0) d](/filings/0001213900-24-098471.md) | [(0.9) d](/filings/0001213900-25-026431.md) | [(1.0)](/filings/0001213900-25-044239.md) | [(1.3) d](/filings/0001213900-25-071724.md) | [(13.2) d](/filings/0001628280-25-052343.md) | [(6.1) d](/filings/0001628280-26-019879.md) | [(5.6)](/filings/0001628280-26-034805.md) | [(4.4) d](/filings/0001628280-26-054985.md) | [(31.0)](/filings/0001628280-26-034805.md) | [(8.4) d](/filings/0001628280-26-054985.md) |
| Capital expenditure | $m | not reported | not reported | not reported | [0.0 d](/filings/0001213900-25-026431.md) | [0.0](/filings/0001213900-25-044239.md) | [0.0 d](/filings/0001213900-25-071724.md) | [0.2 d](/filings/0001628280-25-052343.md) | [(0.2) d](/filings/0001628280-26-019879.md) | [0.1](/filings/0001628280-26-034805.md) | not reported | [0.0](/filings/0001628280-26-034805.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-06-30) | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.1](/filings/0001213900-23-067069.md) | [10.3](/filings/0001213900-23-086956.md) | [10.2](/filings/0001213900-24-043619.md) | [2.7](/filings/0001213900-24-069032.md) | [2.8](/filings/0001213900-24-098471.md) | [2.8](/filings/0001213900-25-044239.md) | [3.0](/filings/0001213900-25-071724.md) | [2.2](/filings/0001628280-25-052343.md) | [2.3](/filings/0001628280-26-034805.md) | [2.3](/filings/0001628280-26-054985.md) | [61.6](/filings/0001628280-26-034805.md) | [75.3](/filings/0001628280-26-054985.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.